Humacyte (HUMA) Expected to Announce Earnings on Monday

Key Points

• Humacyte (HUMA) is expected to announce its Q2 2025 earnings on August 12th, with analysts projecting an earnings loss of ($0.15) per share and revenue of $0.94 million.
• The company's stock recently rose by 1.1%, closing at $2.29, and has a current market capitalization of $354.45 million.
• Analyst ratings are mixed, with one investment analyst giving a sell rating, while others have set price targets ranging from $4.00 to $25.00, reflecting varied outlooks on the stock's potential.

Humacyte (NASDAQ:HUMA - Get Free Report) is expected to be announcing its Q2 2025 earnings results before the market opens on Monday, August 11th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $0.94 million for the quarter.

Humacyte (NASDAQ:HUMA - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.09. The company had revenue of $0.52 million during the quarter, compared to the consensus estimate of $0.46 million. On average, analysts expect Humacyte to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Humacyte Trading Up 0.4%

Shares of NASDAQ:HUMA traded up $0.01 during trading on Friday, hitting $2.48. The company had a trading volume of 10,022,070 shares, compared to its average volume of 3,966,835. The stock has a market cap of $384.70 million, a price-to-earnings ratio of -3.59 and a beta of 1.90. Humacyte has a one year low of $1.15 and a one year high of $8.24. The company has a fifty day simple moving average of $2.40 and a two-hundred day simple moving average of $2.54. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.68 and a quick ratio of 3.28.

Institutional Investors Weigh In On Humacyte

A hedge fund recently raised its stake in Humacyte stock. Geode Capital Management LLC increased its holdings in Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 33.4% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 2,948,508 shares of the company's stock after acquiring an additional 738,142 shares during the period. Geode Capital Management LLC owned approximately 1.90% of Humacyte worth $6,163,000 at the end of the most recent quarter. Institutional investors own 44.71% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Benchmark reduced their price objective on Humacyte from $17.00 to $14.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. D. Boral Capital restated a "buy" rating and set a $25.00 price objective on shares of Humacyte in a report on Wednesday, July 23rd. HC Wainwright assumed coverage on Humacyte in a report on Wednesday, May 14th. They set a "buy" rating and a $4.00 price objective on the stock. Finally, Wall Street Zen upgraded Humacyte from a "sell" rating to a "hold" rating in a report on Saturday. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $11.71.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.